Black Diamond Therapeutics, BDTX-1535 and NSCLC
Black Diamond reports encouraging Phase 2 data for BDTX-1535
Black Diamond Therapeutics (NASDAQ:BDTX) reported encouraging Phase 2 data for its drug candidate BDTX-1535 in the treatment of patients with recurrent EGFR-mutant non-small cell lung cancer, or NSCLC.
Buy Rating on Black Diamond Therapeutics: Promising Phase 2 Results for BDTX-1535 in NSCLC Treatment
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Black Diamond Therapeutics (BDTX – Research Report). The
Black Diamond Therapeutics Gains On Positive Phase 2 Data For BDTX-1535 In Patients With NSCLC
(RTTNews) - Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or refractory non-small cell lung cancer also known as NSCLC, caused by epidermal growth factor receptor or EGFR mutations. Following this news, the stock is up 40% in the pre-market trade.
Black Diamond Therapeutics Shares Jump on Positive Data for Cancer Treatment
Shares in Black Diamond Therapeutics rose after the company outlined positive initial data from Phase 2 trials of BDTX-1535, an oral cancer treatment. Shares were up 46% in premarket trading at $6.94.
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer,
FierceBiotech1d
Black Diamond, Ideaya entertain registrational trial ideas as cancer drugs show midstage promise
Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported initial Phase 2 data of BDTX-1535. The data demonstrated encouraging ...
ENDPOINTS NEWS1d
Black Di­a­mond treads wa­ter on small snap­shot of Phase 2 lung can­cer da­ta
Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its ...
Emma Coronel Walks the Runway in Milan for April Black Diamond
Emma Coronel, the wife of El Chapo, walked the runway yesterday, Sunday, September 22, in Milan in a wedding dress for April ...
The Cool Down on MSN7d
New solar project expected to be one of the largest in the nation: 'Can help unlock new clean energy at a rate that matches the pace and scale of demand growth'
This development is exciting because it's moving us toward a cleaner yet more climate-resilient grid. New solar project ...
Business Insider6d
Buy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment Advances
Black Diamond Therapeutics (BDTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating ...
mtnweekly.com21h
Black Diamond Traverse Ski Poles Review
Black Diamond’s Traverse 3 poles are simplicity refined. The Traverse 3 is a 125cm touring pole in 3 sections, a magical ...
Voiceofmotown on MSN21h
WVU Projected to Go Bowling for the Black Diamond Trophy
Neal Brown, who is coming off of a 9-win campaign in 2023, will have to find four more wins if he hopes for his team to ...